TipRanks
Genmab A/S (DE:GE91)
FRANKFURT:GE91
Germany Market
GE91
Genmab
RESEARCH TOOLSreports

Genmab (GE91) Stock News & Sentiment

3 Followers
Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment
Premium
Market News
Genmab Stock (GMAB) Soars Over 30% on Strong Phase 3 Results for the Company’s Head and Neck Cancer Treatment
3d ago
GMAB
Genmab’s Petosemtamab Combo Halves Risk of Death in Phase 3 Head and Neck Cancer Trial
Premium
Company Announcements
Genmab’s Petosemtamab Combo Halves Risk of Death in Phase 3 Head and Neck Cancer Trial
3d ago
6K
GMAB
Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target
Premium
Ratings
Genmab: Advancing Oncology Assets Support Buy Rating and Unchanged $50 Price Target
5d ago
GMAB
Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK
Premium
Ratings
Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK
5d ago
GMAB
Genmab’s Rina-S Delivers Breakthrough Phase 3 Results in Platinum-Resistant Ovarian Cancer
Premium
Company Announcements
Genmab’s Rina-S Delivers Breakthrough Phase 3 Results in Platinum-Resistant Ovarian Cancer
8d ago
6K
GMAB
Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target
Premium
Ratings
Genmab Maintained at Buy as DARZALEX Strength and Oncology Pipeline Support Unchanged $50 Price Target
12d ago
GMAB
Genmab Reports USD 4.2 Billion in Q3 2026 DARZALEX Net Sales
Premium
Company Announcements
Genmab Reports USD 4.2 Billion in Q3 2026 DARZALEX Net Sales
18d ago
6K
GMAB
More DE:GE91 News >

GE91 News on the Web

Genmab: Robust Oncology Data Drive Buy Rating and Price Target Increase to 3,200 DKK
TipRanks News
Bullish
Genmab upgraded to Overweight from Neutral at JPMorgan
TipRanks News
Bullish
Genmab A/S (0MGB) Gets a Buy from Barclays
TipRanks News
Bullish
Genmab (GMAB) and Incyte Launch Trial for KRAS G12D Colorectal Cancer Therapy Combo
GuruFocus News
Bullish
Incyte, Genmab announce clinical trial collaboration to evaluate INCB161734
TipRanks News
Bullish
Genmab announces updated analyses from Phase 2 trial of petosemtamab
TipRanks News
Bullish
Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer
rttnews
Neutral
GENMAB A/S -SP ADR (NASDAQ:GMAB) Eyes Breakout as Technical Strength Builds
Chartmill
Bullish

News Score - Last 7 Days

Very Positive
DE:GE91
Sector Average
Media Buzz
This Week41 articles
Weekly Average11 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is DE:GE91’s Media Buzz Sentiment?
41 articles about DE:GE91 were published this week. In an average week, 11 articles are published.
    What is DE:GE91’s weekly average amount of articles?
    In an average week, 11 articles about DE:GE91 are published.
      What is DE:GE91’s News Sentiment?
      100% of articles about DE:GE91 were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CNCCentene
        GMABGenmab
        LHLabcorp Holdings
        KIDSOrthoPediatrics
        DXCMDexcom
        Showing the stocks with the most bullish news sentiment over the past week